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EARLIER TREATMENT OF NMDAR ANTIBODY
ENCEPHALITIS IN CHILDREN RESULTS IN A
BETTER OUTCOME
The natural history of NMDA receptor (NMDAR)
antibody encephalitis in adults and children is altered
by treatment with immunosuppressive therapy or
tumor removal.1 In adult cohorts, early initiation of
immunotherapy appears to be beneficial.1,2 In the larg-
est series to date, Titulaer et al.1 demonstrated that
earlier treatment was associated with a modified
Rankin Scale (mRS) score of 2 or less in a cohort of
501 adults and children (univariate analysis p5 0.009,
multivariable analysis p, 0.0001). Multivariable anal-
ysis on 177 children within the cohort showed that
earlier treatment was associated with an mRS score
of 2 or less, although this did not reach statistical sig-
nificance (p 5 0.067).1 An mRS score of 2 indicates
slight disability and that the patient is unable to carry
out all previous activities.
We performed a literature review of all first presen-
tation cases of pediatric NMDAR antibody encephali-
tis to determine whether early treatment with
immunomodulatory therapy is associated with a better
outcome (see search criteria in appendix e-1 at
Neurology.org/nn).
From 43 articles identified (appendix e-1, figure
e-1), information was available on 80 children #17
years of age (56 female, median age 8 years, inter-
quartile range [IQR] 4–14 years, range 1.3–17 years)
reported across 34 articles with care from at least 34
institutions (table e-1). We dichotomized outcome
into complete recovery (pediatric mRS score 5 0)
or incomplete recovery (mRS score $ 1).
Fifty-seven percent (41) received IV steroids as the
first agent, 11.3% (9) received IV immunoglobulin
(IVIg), 28.7% (23) had IVIg and methylprednisolone
simultaneously, 2 children had tumor removal, and 5
children had no treatment (appendix e-1).
At follow-up (median 12 months, IQR 4.5–24
months, range 1.3–54 months), 33 (41%) children
had recovered completely (mRS score 5 0), whereas
47 (59%) children had an incomplete recovery (mRS
score $ 1) based on evaluation by their treating
physicians and/or families. There was no difference
in median time to follow-up or median age at onset
between children who recovered fully and those who
did not (see table 1). There was no difference in
median mRS score at nadir between children who
made a full recovery (mRS score 5, IQR 4–5, range
3–5) and children who made an incomplete recovery
(mRS score 4, IQR 3–5, range 3–5) (p 5 0.2).
The important finding from this review is that the
median time from symptom onset to initiation of treat-
ment was 15 days (IQR 7–21 days, range 3–182 days) in
children who recovered completely (mRS score5 0) and
21 days (IQR 15–40 days, range 5–365 days) in those
who had not recovered completely at follow-up (p 5
0.014, Wilcoxon Mann-Whitney nonparametric test).
We illustrate the direct correlation between out-
come and days to initiation of treatment as a box plot
(see figure e-2).
Discussion. Our retrospective review suggests that
earlier treatment of NMDAR antibody encephalitis
in children results in better outcomes. This is consis-
tent with a previous report by Titulaer et al.1 In our
study, children who recovered completely at follow-
up (mRS score5 0) were treated a median of 15 days
from symptom onset vs 21 days in children who did
not completely recover. The median time of follow-
up was 1 year in all patients, and because recovery
from NMDAR antibody encephalitis can be very
slow and take 18 months or longer,1 some patients
may recover further. As such, our data may simply
reflect an earlier recovery, which nevertheless
may have a large benefit on quality of life and
educational attainment. Although NMDAR
antibody has been shown to mediate its effect by
receptor internalization, which is reversible,3 factors
such as the extent of secondary disturbance in
synaptogenesis as a result of NMDAR binding by
antibodies,4 manifesting as persisting functional and
structural advanced MRI changes,5 may exert a larger
influence on the developing CNS.
There are limitations to this study. First, selection
bias may arise from reporting bias and the subsequent
limited author response allowing analysis of only 80
of the potential 300 cases. Single cases are often pub-
lished because of atypical features, and our study
included 23 case reports. Second, 29 of the 80 pa-
tients were diagnosed on serum analysis alone, which
Neurology.org/nn © 2015 American Academy of Neurology 1
may yield false-positive results6; however, patients
included in this study did have a clinical phenotype
compatible with NMDAR encephalitis. Third, the
outcome is dichotomous—the mRS was designed to
describe outcomes in the context of stroke in adults,
focusing primarily on physical deficits, and is not a
sensitive marker of cognitive deficits.
Prospective longitudinal studies addressing these
limitations will be required to confirm whether earlier
treatment results in better measurable outcomes.
Early recognition of the variable symptoms of
NMDAR antibody encephalitis and more widespread
availability of rapid diagnostic tests7 will facilitate
early initiation of optimal therapy, although empiric
therapy may be warranted when children have clinical
manifestations that are consistent with NMDAR and
other autoimmune encephalitis.
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Table 1 Comparison of the clinical features between children who recovered
completely and those who did not
Complete recovery
at follow-up (n 5 33)
Incomplete recovery
at follow-up (n 5 47)
p
Value
Median time of follow-up, mo (IQR) 12 (5–24) 12 (4–24) 0.864
Range, mo 2–54 1.3–36
Median age at symptom onset,
y (IQR)
9 (3.4–14) 8 (5–13) 0.791
Range, y 2.3–17 1.3–16
Median mRS score at nadir (IQR) 5 (4–5) 4 (3–5) 0.2
Range 3–5 3–5
Percentage in each group given
empiric therapy
89 73 0.175
Median time from symptom onset
to treatment, d (IQR)
15 (7–21) 21 (15–40) 0.014a
Range, d 3–182 5–365
Number of therapies required to
induce remission, % (n)
0.968
1 25 (8) 9.5 (4)
2 40.6 (13) 54.8 (23)
3 25 (8) 21.4 (9)
4 or more 9.4 (3) 14.3 (6)
Median mRS score at follow-up
(IQR)
0 (0–0) 2 (1–3)
Range 0–0 1–5
Abbreviations: IQR 5 inter quartile range; mRS 5 modified Rankin Scale.
a Significant value.
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